Dishman Pharma invests $20m in new API facility

6338 Investors following Dishman Pharma. Share this News with them.

0

Like this story, share it with millions of investors on M3

Dishman Pharma invests $20m in new API facility

In an interview with CNBC-TV18, VVS Murthy, CFO, Dishman Pharma, spoke about the latest happenings in his company and sector.

Post your opinion here

 

0

Tweet

Share on Tumblr

Excerpts from Midcap Radar on CNBC-TV18 Watch the full show » RELATED NEWS Consolidated revenues to grow 20% next year: Dishman Pharma Dishman Pharma Q3 cons PAT down at Rs 33.1 cr ALSO READ See latest News about Dishman Pharma See previous management interviews See what other Experts & Brokerages are saying about Dishman Pharma Dishman Pharma BSE | NSE 10/02/12 Are Mutual Funds betting on Dishman Pharma?

In an interview with CNBC-TV18, VVS Murthy, CFO, Dishman Pharma , spoke about the latest happenings in his company and sector. 

Here is a verbatim transcript of the exclusive interview with VVS Murthy on CNBC-TV18. Also watch the accompanying video.

Q: We understand your Bavla facilities have been approved now, could you tell us what kind of revenue generation are you expecting from this?

A: It's too early to give any projections about revenue generations from this particular approval. The first step was to get approval of TGA Australia for our products and now we have to discuss with our customers to finalize our products and then I can give you some revenue guidance.

Q: Give us an idea atleast as to when you may start revenue generation?

A: Second half of FY11.